|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cohen EE, Lingen MW and Vokes EE: The
expanding role of systemic therapy in head and neck cancer. J Clin
Oncol. 22:1743–1752. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cooper JS, Pajak TF, Forastiere AA, Jacobs
J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, et
al; Radiation Therapy Oncology Group 9501/Intergroup. Postoperative
concurrent radiotherapy and chemotherapy for high-risk
squamous-cell carcinoma of the head and neck. N Engl J Med.
350:1937–1944. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Biscardi JS, Tice DA and Parsons SJ:
c-Src, receptor tyrosine kinases, and human cancer. Adv Cancer Res.
76:61–119. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Abram CL and Courtneidge SA: Src family
tyrosine kinases and growth factor signaling. Exp Cell Res.
254:1–13. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schlessinger J: Cell signaling by receptor
tyrosine kinases. Cell. 103:211–225. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Blume-Jensen P and Hunter T: Oncogenic
kinase signalling. Nature. 411:355–365. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Prenzel N, Fischer OM, Streit S, Hart S
and Ullrich A: The epidermal growth factor receptor family as a
central element for cellular signal transduction and
diversification. Endocr Relat Cancer. 8:11–31. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Marmor MD, Skaria KB and Yarden Y: Signal
transduction and oncogenesis by ErbB/HER receptors. Int J Radiat
Oncol Biol Phys. 58:903–913. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nicholson RI, Gee JM and Harper ME: EGFR
and cancer prognosis. Eur J Cancer. 37(Suppl 4): S9–S15. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Grandis JR and Tweardy DJ: Elevated levels
of transforming growth factor α and epidermal growth factor
receptor messenger RNA are early markers of carcinogenesis in head
and neck cancer. Cancer Res. 53:3579–3584. 1993.PubMed/NCBI
|
|
13
|
Rubin Grandis J, Melhem MF, Gooding WE,
Day R, Holst VA, Wagener MM, Drenning SD and Tweardy DJ: Levels of
TGF-α and EGFR protein in head and neck squamous cell carcinoma and
patient survival. J Natl Cancer Inst. 90:824–832. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ang KK, Berkey BA, Tu X, Zhang H-Z, Katz
R, Hammond EH, Fu KK and Milas L: Impact of epidermal growth factor
receptor expression on survival and pattern of relapse in patients
with advanced head and neck carcinoma. Cancer Res. 62:7350–7356.
2002.PubMed/NCBI
|
|
15
|
Galizia G, Lieto E, De Vita F, Orditura M,
Castellano P, Troiani T, Imperatore V and Ciardiello F: Cetuximab,
a chimeric human mouse anti-epidermal growth factor receptor
monoclonal antibody, in the treatment of human colorectal cancer.
Oncogene. 26:3654–3660. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ,
Kussie P and Ferguson KM: Structural basis for inhibition of the
epidermal growth factor receptor by cetuximab. Cancer Cell.
7:301–311. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Boeckx C, Baay M, Wouters A, Specenier P,
Vermorken JB, Peeters M and Lardon F: Anti-epidermal growth factor
receptor therapy in head and neck squamous cell carcinoma: Focus on
potential molecular mechanisms of drug resistance. Oncologist.
18:850–864. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rebucci M, Peixoto P, Dewitte A, Wattez N,
De Nuncques MA, Rezvoy N, Vautravers-Dewas C, Buisine MP, Guerin E,
Peyrat JP, et al: Mechanisms underlying resistance to cetuximab in
the HNSCC cell line: Role of AKT inhibition in bypassing this
resistance. Int J Oncol. 38:189–200. 2011.
|
|
19
|
Ohnishi Y, Minamino Y, Kakudo K and Nozaki
M: Resistance of oral squamous cell carcinoma cells to cetuximab is
associated with EGFR insensitivity and enhanced stem cell-like
potency. Oncol Rep. 32:780–786. 2014.PubMed/NCBI
|
|
20
|
Bakin AV, Rinehart C, Tomlinson AK and
Arteaga CL: p38 mitogen-activated protein kinase is required for
TGFbeta-mediated fibroblastic transdifferentiation and cell
migration. J Cell Sci. 115:3193–3206. 2002.PubMed/NCBI
|
|
21
|
Pal HC, Sharma S, Strickland LR, Agarwal
J, Athar M, Elmets CA and Afaq F: Delphinidin reduces cell
proliferation and induces apoptosis of non-small-cell lung cancer
cells by targeting EGFR/VEGFR2 signaling pathways. PLoS One.
8:e772702013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Morozevich GE, Kozlova NI, Ushakova NA,
Preobrazhenskaya ME and Berman AE: Integrin α5β1 simultaneously
controls EGFR-dependent proliferation and Akt-dependent
pro-survival signaling in epidermoid carcinoma cells. Aging
(Albany, NY). 4:368–374. 2012.
|
|
23
|
Maa MC, Leu TH, McCarley DJ, Schatzman RC
and Parsons SJ: Potentiation of epidermal growth factor
receptor-mediated oncogenesis by c-Src: Implications for the
etiology of multiple human cancers. Proc Natl Acad Sci USA.
92:6981–6985. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Simons K and Ikonen E: Functional rafts in
cell membranes. Nature. 387:569–572. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu W, Graves LM, Gill GN, Parsons SJ and
Samet JM: Src-dependent phosphorylation of the epidermal growth
factor receptor on tyrosine 845 is required for zinc-induced Ras
activation. J Biol Chem. 277:24252–24257. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bolard J: How do the polyene macrolide
antibiotics affect the cellular membrane properties? Biochim
Biophys Acta. 864:257–304. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Montesano R, Vassalli P and Orci L:
Structural heterogeneity of endocytic membranes in macrophages as
revealed by the cholesterol probe, filipin. J Cell Sci. 51:95–107.
1981.PubMed/NCBI
|
|
28
|
Santos NC, Ter-Ovanesyan E, Zasadzinski
JA, Prieto M and Castanho MA: Filipin-induced lesions in planar
phospholipid bilayers imaged by atomic force microscopy. Biophys J.
75:1869–1873. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang B, Peng F, Wu D, Ingram AJ, Gao B
and Krepinsky JC: Caveolin-1 phosphorylation is required for
stretch-induced EGFR and Akt activation in mesangial cells. Cell
Signal. 19:1690–1700. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hynes NE and Lane HA: ERBB receptors and
cancer: The complexity of targeted inhibitors. Nat Rev Cancer.
5:341–354. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shen X and Kramer RH: Adhesion-mediated
squamous cell carcinoma survival through ligand-independent
activation of epidermal growth factor receptor. Am J Pathol.
165:1315–1329. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lambert S, Vind-Kezunovic D, Karvinen S
and Gniadecki R: Ligand-independent activation of the EGFR by lipid
raft disruption. J Invest Dermatol. 126:954–962. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Goldstein NI, Prewett M, Zuklys K,
Rockwell P and Mendelsohn J: Biological efficacy of a chimeric
antibody to the epidermal growth factor receptor in a human tumor
xenograft model. Clin Cancer Res. 1:1311–1318. 1995.PubMed/NCBI
|
|
34
|
Frisch SM and Francis H: Disruption of
epithelial cell-matrix interactions induces apoptosis. J Cell Biol.
124:619–626. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Frisch SM, Vuori K, Ruoslahti E and
Chan-Hui PY: Control of adhesion-dependent cell survival by focal
adhesion kinase. J Cell Biol. 134:793–799. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Meredith JE Jr, Fazeli B and Schwartz MA:
The extracellular matrix as a cell survival factor. Mol Biol Cell.
4:953–961. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu Z, Li H, Wu X, Yoo BH, Yan SR, Stadnyk
AW, Sasazuki T, Shirasawa S, LaCasse EC, Korneluk RG, et al:
Detachment-induced upregulation of XIAP and cIAP2 delays anoikis of
intestinal epithelial cells. Oncogene. 25:7680–7690. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rosen K, Coll ML, Li A and Filmus J:
Transforming growth factor-alpha prevents detachment-induced
inhibition of c-Src kinase activity, Bcl-XL down-regulation, and
apoptosis of intestinal epithelial cells. J Biol Chem.
276:37273–37279. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu P, Begley M, Michowski W, Inuzuka H,
Ginzberg M, Gao D, Tsou P, Gan W, Papa A, Kim BM, et al:
Cell-cycle-regulated activation of Akt kinase by phosphorylation at
its carboxyl terminus. Nature. 508:541–545. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lajoie P, Goetz JG, Dennis JW and Nabi IR:
Lattices, rafts, and scaffolds: Domain regulation of receptor
signaling at the plasma membrane. J Cell Biol. 185:381–385. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Williams TM, Hassan GS, Li J, Cohen AW,
Medina F, Frank PG, Pestell RG, Di Vizio D, Loda M and Lisanti MP:
Caveolin-1 promotes tumor progression in an autochthonous mouse
model of prostate cancer: Genetic ablation of Cav-1 delays advanced
prostate tumor development in tramp mice. J Biol Chem.
280:25134–25145. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Quann K, Gonzales DM, Mercier I, Wang C,
Sotgia F, Pestell RG, Lisanti MP and Jasmin JF: Caveolin-1 is a
negative regulator of tumor growth in glioblastoma and modulates
chemosensitivity to temozolomide. Cell Cycle. 12:1510–1520. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Couet J, Sargiacomo M and Lisanti MP:
Interaction of a receptor tyrosine kinase, EGF-R, with caveolins.
Caveolin binding negatively regulates tyrosine and serine/threonine
kinase activities. J Biol Chem. 272:30429–30438. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Blay J and Brown KD: Epidermal growth
factor promotes the chemotactic migration of cultured rat
intestinal epithelial cells. J Cell Physiol. 124:107–112. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chen JD, Kim JP, Zhang K, Sarret Y, Wynn
KC, Kramer RH and Woodley DT: Epidermal growth factor (EGF)
promotes human keratinocyte locomotion on collagen by increasing
the alpha 2 integrin subunit. Exp Cell Res. 209:216–223. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Fujii K, Dousaka-Nakajima N and Imamura S:
Epidermal growth factor enhancement of HSC-1 human cutaneous
squamous carcinoma cell adhesion and migration on type I collagen
involves selective up-regulation of alpha 2 beta 1 integrin
expression. Exp Cell Res. 216:261–272. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Matthay MA, Thiery JP, Lafont F, Stampfer
F and Boyer B: Transient effect of epidermal growth factor on the
motility of an immortalized mammary epithelial cell line. J Cell
Sci. 106:869–878. 1993.PubMed/NCBI
|
|
49
|
Basson MD, Modlin IM and Madri JA: Human
enterocyte (Caco-2) migration is modulated in vitro by
extracellular matrix composition and epidermal growth factor. J
Clin Invest. 90:15–23. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Goetz JG, Lajoie P, Wiseman SM and Nabi
IR: Caveolin-1 in tumor progression: The good, the bad and the
ugly. Cancer Metastasis Rev. 27:715–735. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Boscher C and Nabi IR: Galectin-3- and
phospho-caveolin-1-dependent outside-in integrin signaling mediates
the EGF motogenic response in mammary cancer cells. Mol Biol Cell.
24:2134–2145. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Vermorken JB, Mesia R, Rivera F, Remenar
E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol
D, et al: Platinum-based chemotherapy plus cetuximab in head and
neck cancer. N Engl J Med. 359:1116–1127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Bonner JA, Harari PM, Giralt J, Azarnia N,
Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al:
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head
and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Sartore-Bianchi A, Martini M, Molinari F,
Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P,
De Dosso S, Mazzucchelli L, et al: PIK3CA mutations in colorectal
cancer are associated with clinical resistance to EGFR-targeted
monoclonal antibodies. Cancer Res. 69:1851–1857. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Sartore-Bianchi A, Di Nicolantonio F,
Nichelatti M, Molinari F, De Dosso S, Saletti P, Martini M, Cipani
T, Marrapese G, Mazzucchelli L, et al: Multi-determinants analysis
of molecular alterations for predicting clinical benefit to
EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One.
4:e72872009. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Laurent-Puig P, Lievre A and Blons H:
Mutations and response to epidermal growth factor receptor
inhibitors. Clin Cancer Res. 15:1133–1139. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
De Rock W, Lambrechts D and Tejpar S:
K-ras mutations and cetuximab in colorectal cancer. N Engl J Med.
360:8342009.
|
|
58
|
De Roock W, Claes B, Bernasconi D, De
Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V,
Papamichael D, Laurent-Puig P, et al: Effects of KRAS, BRAF, NRAS,
and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy
in chemotherapy-refractory metastatic colorectal cancer: A
retrospective consortium analysis. Lancet Oncol. 11:753–762. 2010.
View Article : Google Scholar : PubMed/NCBI
|
